ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
4 hedge funds and large institutions have $110K invested in ELITE PHARMACEUTICAL in 2014 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
25% less capital invested
Capital invested by funds: $145K → $110K (-$35.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$17K |
| 2 |
GIA
Guyasuta Investment Advisors
Pittsburgh,
Pennsylvania
|
+$6.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$24.1K |
ELI Hedge Fund Activity: Q4 2014 in Review
4 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2014, worth a combined $110K — down 25% from $145K a quarter earlier.
Fund positioning in ELI was balanced in Q4 2014: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $17K. The largest seller was Janney Montgomery Scott, exiting entirely with an estimated $24.1K sold.
- 4 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $110K of ELITE PHARMACEUTICAL stock for Q4 2014, down 25% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q4 2014 and 1 closed out, a net change of 0 holders.
- The largest ELITE PHARMACEUTICAL buyer in Q4 2014 was Ameriprise, an estimated $17K added.
- The largest ELITE PHARMACEUTICAL seller in Q4 2014 was Janney Montgomery Scott, an estimated $24.1K sold.
Based on aggregated 13F filings for Q4 2014.